Management of myelofibrosis after ruxolitinib failure

Myelofibrosis is a BCR-ABL1–negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, constitutional symptoms, leukemic progression, and shortened survival. Constitutive activation of the Janus kinase/signal transducer...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, Claire N, Schaap, Nicolaas, Mesa, Ruben A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237516/
https://www.ncbi.nlm.nih.gov/pubmed/32198525
http://dx.doi.org/10.1007/s00277-020-04002-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237516/
https://www.ncbi.nlm.nih.gov/pubmed/32198525
http://dx.doi.org/10.1007/s00277-020-04002-9

Ejemplares similares